Skip to main content
SpringerLink
Log in

Alectinib/bevacizumab/docetaxel

Lack of efficacy and drug resistance: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Yang P, et al. Identification of novel alectinib-resistant ALK mutation G1202K with sensitization to Lorlatinib: A case report and in silico structural modelling. OncoTargets and Therapy 14: 2131-2138, Jan 2021. Available from: URL: https://www.dovepress.com/getfile.php?fileID=67986

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alectinib/bevacizumab/docetaxel. Reactions Weekly 1879, 22 (2021). https://doi.org/10.1007/s40278-021-04506-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-04506-0

Search

Navigation